| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5274513
Max Phase: Preclinical
Molecular Formula: C23H27N7O
Molecular Weight: 417.52
Associated Items:
Representations
Canonical SMILES: Cc1cncn1CCCNC(=O)N(Cc1cccnc1)c1ccc2c(C)n(C)nc2c1
Standard InChI: InChI=1S/C23H27N7O/c1-17-13-25-16-29(17)11-5-10-26-23(31)30(15-19-6-4-9-24-14-19)20-7-8-21-18(2)28(3)27-22(21)12-20/h4,6-9,12-14,16H,5,10-11,15H2,1-3H3,(H,26,31)
Standard InChI Key: BLVPDKRLZLPNKZ-UHFFFAOYSA-N
Associated Targets(Human)
Glutaminyl-peptide cyclotransferase 1121 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 417.52 | Molecular Weight (Monoisotopic): 417.2277 | AlogP: 3.59 | #Rotatable Bonds: 7 |
| Polar Surface Area: 80.87 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 7.33 | CX LogP: 1.64 | CX LogD: 1.46 |
| Aromatic Rings: 4 | Heavy Atoms: 31 | QED Weighted: 0.47 | Np Likeness Score: -1.78 |
References
| 1. Van Manh N, Hoang VH, Ngo VTH, Kang S, Jeong JJ, Ha HJ, Kim H, Kim YH, Ann J, Lee J.. (2022) Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents., 244 [PMID:36265279] [10.1016/j.ejmech.2022.114837] |
Source
Source(1):